drugset / Trial / NCT03687632
ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects
NaSingle-groupOpen-labelTreatment
Summary
The primary aim of the study is to evaluate the clinical response of ST266 treated subjects with persistent corneal epithelial defects during 28 days of therapy. The secondary endpoint is the response rate within 14 days of treatment.
Timeline
- Start
- 2019-06-10
- Primary completion
- 2020-08-18
- Completion
- 2020-08-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ST266 | Protein / enzyme biologic | 1 unknown | Topical |